Invion Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
737.70
Cost of Goods Sold (COGS) incl. D&A
1,954.60
1,343.20
1,320.40
1,245.00
-
Gross Income
1,954.60
1,343.20
1,320.40
1,245.00
-
SG&A Expense
6,507.00
13,679.40
4,879.10
840.40
1,664.20
EBIT
8,461.60
15,022.60
6,199.60
2,085.40
2,251.60
Unusual Expense
-
-
141.00
4,400.00
2,000.00
Non Operating Income/Expense
94.00
883.50
127.80
174.00
12.50
Interest Expense
-
64.30
166.80
144.40
117.90
Pretax Income
8,274.70
15,944.10
6,094.60
6,455.40
4,381.00
Income Tax
1,390.80
2,902.90
1,646.90
4,255.60
489.10
Consolidated Net Income
6,883.90
13,041.20
4,447.70
2,199.70
4,870.10
Net Income
6,883.90
13,041.20
4,447.70
2,199.70
4,870.10
Net Income After Extraordinaries
6,883.90
13,041.20
4,447.70
2,199.70
4,870.10
Net Income Available to Common
6,883.90
13,041.20
4,447.70
2,199.70
4,870.10
EPS (Basic)
0.01
0.02
0.00
0.00
0.00
Basic Shares Outstanding
685,524.70
767,945.20
1,362,901.80
1,589,496.60
3,813,788.40
EPS (Diluted)
0.01
0.02
0.00
0.00
0.00
Diluted Shares Outstanding
685,524.70
767,945.20
1,362,901.80
1,589,496.60
3,813,788.40
EBITDA
6,507.00
13,679.40
4,879.20
840.40
926.50
Non-Operating Interest Income
92.90
26.20
3.10
0.40
1.10

About Invion

View Profile
Address
722 High Street
Melbourne Victoria (VIC) 3102
Australia
Employees -
Website http://www.inviongroup.com
Updated 07/08/2019
Invion Ltd. engages in the development of treatments for respiratory and autoimmune disease. It develops the following drug assets: nadolol, zafirlukast, and ala-Cpn10. The company was founded on October 11, 2000 and is headquartered in Chermside, Australia.